Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
Tempest Therapeutics (TPST) announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback